Has Aldea Hit On A Sober Approach To Alcohol-Intoxication Therapy?
This article was originally published in The Pink Sheet Daily
Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.
You may also be interested in...
Rusnano Teams With Domain Associates To Co-Fund Life Sciences Companies And Establish Pharma JV In Russia
Russian sovereign fund is co-investing with Domain in the VC’s portfolio life sciences companies, and the pair also will fund a manufacturing facility in Russia.
Titan says compliance and abuse-resistance will hook payers on new long-acting formulations vs. low-cost generics.
As awareness of the biology of addiction slowly begins to take hold among the general population, medications could wind up being the next best thing to a Higher Power in helping to keep alcoholics sober